Skip to content

OUR
Journal Publications

Home / Kibow's Journal publications

Clinical Trials / Current Efforts

Why clinical trials?

Supported by Visionary & Distinguished Nephrologists and Scientists

“WILL THE BOWEL BE THE KIDNEY OF THE FUTURE”

SYMPOSIUM AT THE INTERNATIONAL SOCIETY OF ARTIFICIAL INTERNAL ORGANS IN EDINBURGH, SCOTLAND. Aug 04, 1999

Utenim ad minim eniami quis nostrud exer.

Utenim ad minim eniami quis nostrud exer.

Utenim ad minim eniami quis nostrud exer.

Utenim ad minim eniami quis nostrud exer.

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Why kidney health supplement to drug pathway?

Change is the law of life in all aspects, whether it is personal or professional, and as well, business strategy matters. Those who look only to the past or present are certain to miss the future opportunities. Hence, timing is most certainly one of the critical elements of operating a profitable business– especially when launching a new enterprise or product, or the repositioning of a company in the marketplace. Generally, in personal or professional life, one can precisely control the timing on several matters or aspects. However, achieving the right timing in a business endeavor is not something that can happen easily or quickly. What one can do, however, is make a concerted effort to anticipate when it might arrive – and be ready to take full advantage of it the moment it does. After twenty-two years of successful business operations as a kidney health dietary supplement company, the timing has finally come for Kibow®. Hence Kibow® is transitioning to a pharmaceutical drug, ultimately reaching out, accomplishing, and achieving the multi-billion-dollar business potential with its novel and breakthrough “Enteric Dialysis®” platform technology. This revolutionary generation of product formulation is a continuation of its two decades of pharma like clinically validated platform technology. The founder and his team – i.e., current employees, the scientific advisors, and board of directors strongly support this transition process, and the entire Kibow® team strongly believes this can be accomplished by January 2023.

Kibow® has mostly financed itself – initially with Founders/Family/Friends and subsequently from highly competitive SBIR phase I and II fast-track dual back to back grant awards from NIDDK-NIH and Qualifying Therapeutic Discovery Project (QTDP) Programs. Additionally, the company also obtained a USAID grant funding allocated to India but used exclusively for the US R&D operations and product development on a conditional basis. The company’s breakthrough happened with its substantial licensing income plus royalties derived (since July 2006) from Vetoquinol SA (VETO, a publicly-traded European veterinary company in France). By 2018, end-market sales for Vetoqiunol’s veterinary product, AZODYL®, reached $10 million in the USA and Canada.

 

2019 – Specific Probiotics for Chronic Kidney Disease: A ReviewVIEW (PDF) 

2018 – Reality of “Enteric Dialysis ®” with Probiotics and Prebiotics to Delay the Need of Conventional Dialysis. VIEW (PDF)

2018 – Probiotic supplements prevented oxonic acid induced hyperuricemia and renal damage. VIEW (PDF)

2017 – Probiotics in Kidney Disease. VIEW (PDF)

2017 – Quality of Life in Chronic Kidney Disease(CKD) Patients Using a Synbiotic Dietary Supplement: A Survey. VIEW (PDF)

2015 – Concept and potential of Enteric Dialysis®-Treating the cause not the symptom. VIEW (PDF)

2014 – A Randomized controlled trial of Renadyl™ in Dialysis patients. VIEW (PDF)

2014 – Review of Health status and level of satisfaction of customers with CKD using Renadyl.VIEW (PDF)

2013 – Dose Escalation, Safety, and Impact of Renadyl™_CKD-III-IV_TJU_N&T  VIEW (PDF)

2012 – Probiotics Prebiotics and Synbiotics- Gut and Beyond  VIEW (PDF)

2011 – McCain Azodyl™ study Journal of Zoo and Wildlife Medicine 2011  VIEW (PDF)

2010 – Pilot study probiotic dietary supplement CKD AdvTher 2010  VIEW (PDF)

2009 – Can the bowel substitute for the kidney in advanced renal failure  VIEW (PDF)

2009 – Probiotic dietary supplementation st3&4CKD 6mo Canada CurMedResOpin 2009  VIEW (PDF)

2006 – InVitroIntraintestinal bacteriotherapy ASAIO Journal_2006  VIEW (PDF)

2006 – A Preliminary Clinical Evaluation of Kibow® Biotics – Richard Palmquist  DVM (2)  VIEW (PDF)

2005 – Probiotic Amelioration of Azotemia in 5-6th Nephrectomized Sprague-Dawley Rats  DVM (2)  VIEW (PDF)

Our Mission

 
0
Foundation Date
 
 
0 +
Happy Patients
 
 
0 +
Patents
 

Our Staffs

At Your Service

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium. totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur.

Chef02

Peter Parker

Chef03

Peter Parker

Chef04

Peter Parker

Chef01

Peter Parker

Online Order Form